The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Search Terms:
Investigator: Matthew Kang
Project Title: Neurofilament light and glial fibrillary acidic protein as a diagnostic and prognostic biomarker for mood disorders: A systematic review and meta-analysis
Date: August 20, 2023 at 8:29 pm
Request ID: D2327
Aim 1: Identify the association between neuronal (neurofilament light chain) and glial (glial fibrillary acidic protein) biomarkers in patients with mood and anxiety disorders compared to healthy controls
Aim 2: Identify whether there are any associations between NfL/GFAP and clinical variables of mood and anxiety disorders including symptom severity and cognition
Aim 3:
Aim 4:
Investigator: Julie Wisch
Project Title: Neighborhood Characteristics Associated with Elevated Brain Age Gap
Date: August 15, 2023 at 3:54 pm
Request ID: D2326
Aim 1: To identify neighborhood characteristics associated with accelerated brain aging in aging urban-dwelling adults
Aim 2:
Aim 3:
Aim 4:
Investigator: Julie Wisch
Project Title: Trip Chaining Behavior in Preclinical AD
Date: August 15, 2023 at 3:49 pm
Request ID: D2325
Aim 1: To describe the trip chaining behavior older adult driverss living in the greater St. Louis, MO metroplex and neighboring Illinois
Aim 2: To identify key transition points in the process of aging/the development of preclinical AD when trip chaining behavior shifts.
Aim 3:
Aim 4:
Investigator: Jeremy Strain
Project Title: Blood Brain Barrier Association with WMH Frequency and Expansion
Date: August 14, 2023 at 2:13 pm
Request ID: D2324
Aim 1: 1) Does BBB integrity associate with regional WMH burden and or regional expansion 1a) across the disease spectrum and/or 1b) in preclinical individuals.
Aim 2: 2) Does BBB integrity associate with regional WMH density, as quantified by DTI, 2a) across the disease spectrum and/or 2b) in preclinical individuals
Aim 3: 3) Can WMH and metrics of BBB predict 3a) amyloid positivity and/or 3b) cognitive outcome.
Aim 4:
Investigator: Junie Saint Clair
Project Title: Examining the Predictive Value of Synaptic Dysfunction and Neuronal Injury Measures on Imaging Markers of Disease Presentation and Progression in Alzheimer’s Disease
Date: July 31, 2023 at 6:29 pm
Request ID: D2323
Aim 1: Evaluate association between rates of longitudinal change in CSF levels of Ng, SNAP-25, VILIP-1 and imaging brain changes and cognition in a DIAD cohort.
Aim 2: Evaluate association between rates of longitudinal change in CSF levels of Ng, SNAP-25, VILIP-1 and imaging brain changes and cognition in aged adults LOAD cohort.
Aim 3:
Aim 4:
Investigator: Jeremy Strain
Project Title: Phosphorylation Tau Profile of Aging and AD with TBI
Date: July 20, 2023 at 10:49 am
Request ID: D2322
Aim 1: Do Individuals with a history of TBI have elevated phosphorylation at tau site T217 compared to individuals without a history of TBI?
Aim 2: Do individuals with a history of TBI have a similar or different spatial relationship with magnetic resonance imaging mettrics of neuroddegeneration compared to AD?
Aim 3: Does phosphorylated tau in individuals with a history of TBI associate with cognition?
Aim 4:
Investigator: Gregory Wu
Project Title: MOG in Alzheimer’s Disease
Date: July 19, 2023 at 6:35 pm
Request ID: D2321
Aim 1: Determine whether circulating MOG protein is detectable in AD
Aim 2:
Aim 3:
Aim 4:
Investigator: Manuel Dietrich
Project Title: Validation meta-analysis to identify novel biomarkers for early diagnosis of Alzheimer’s
Date: June 28, 2023 at 8:44 am
Request ID: D2320
Aim 1: Validate and correlate internal bulk RNA-seq findings from human brains of AD patients with SOMAScan proteomics data from tissue, CSF, and plasma.
Aim 2: Compare and replicate internal bulk RNA-seq findings from human brains of AD patients with SOMAScan proteomics data from tissue, CSF, and plasma.
Aim 3:
Aim 4:
Investigator: Beau Ances
Project Title: Predicting Cognitive Outcomes with Brain Age Gap
Date: June 26, 2023 at 2:28 pm
Request ID: D2319
Aim 1: Test whether Brain Age Gap correlates cross-sectionally with measures of cognition
Aim 2: Test whether Brain Age Gap predicts longitudinal cognitive decline
Aim 3: Identify sources of mediation between the relationship between Brain Age Gap and cognition
Aim 4:
Investigator: Nicole S McKay
Project Title: Prevalence of AD-pathology in older adults of the Knight Alzheimer Disease Research Center (ADRC)
Date: June 15, 2023 at 4:43 pm
Request ID: D2318
Aim 1: This proposal extends upon prior work examining the frequencies of imaging-derived -amyloidosis and neurodegeneration, among older adults with normal cognitive function.
Aim 2: Replicate the above-mentioned Jack et al. study using data from the Knight ADRC cohort to determine the extent to which our frequencies of imaging-derived -amyloidosis and neurodegeneration in non-demented participants, aligns with their prior work.
Aim 3: Extend upon prior work by also determining frequencies of commonly used biofluid metrics of AD pathology
Aim 4: Further these findings by considering tauopathy measured using tau-PET